These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18814815)

  • 21. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Gleave M; Fujisawa M
    Urology; 2006 Sep; 68(3):609-14. PubMed ID: 16979705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
    Li Y; Mizutani Y; Shiraishi T; Okihara K; Ukimura O; Kawauchi A; Nonomura N; Fukushima M; Sakai T; Miki T
    Urology; 2007 May; 69(5):988-95. PubMed ID: 17482957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.
    Li H; Kantoff PW; Ma J; Stampfer MJ; George DJ
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1557-61. PubMed ID: 15941972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
    George DJ; Halabi S; Shepard TF; Vogelzang NJ; Hayes DF; Small EJ; Kantoff PW;
    Clin Cancer Res; 2001 Jul; 7(7):1932-6. PubMed ID: 11448906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
    Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Sakamoto A; Sakamoto T; Maruyama H; Sato S; Mizunuma H; Smith SK
    Clin Cancer Res; 2003 Apr; 9(4):1361-9. PubMed ID: 12684405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
    Wang Q; Diao X; Sun J; Chen Z
    Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro.
    McLarty J; Bigelow RL; Smith M; Elmajian D; Ankem M; Cardelli JA
    Cancer Prev Res (Phila); 2009 Jul; 2(7):673-82. PubMed ID: 19542190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
    Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
    Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
    Al-Dissi AN; Haines DM; Singh B; Kidney BA
    Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
    Steiner H; Berger AP; Godoy-Tundidor S; Bjartell A; Lilja H; Bartsch G; Hobisch A; Culig Z
    Eur J Cancer; 2004 May; 40(7):1066-72. PubMed ID: 15093584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma].
    Dales JP; Garcia S; Bonnier P; Duffaud F; Carpentier S; Djemli A; Ramuz O; Andrac L; Lavaut M; Allasia C; Charpin C
    Ann Pathol; 2003 Sep; 23(4):297-305. PubMed ID: 14597894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
    Brychtova S; Bezdekova M; Brychta T; Tichy M
    Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Yamanaka K; Muramaki M; Kurahashi T; Gleave M; Hara I
    Oncol Rep; 2005 Nov; 14(5):1371-5. PubMed ID: 16211311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vascular endothelial growth factor and two types of its receptors in breast cancer].
    Shcherbakov AM; Gershteĭn ES; Anurova OA; Kushlinskiĭ NE
    Vopr Onkol; 2005; 51(3):317-21. PubMed ID: 16279095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of the semaphorin 3A pathway in prostatic cancer.
    Yacoub M; Coulon A; Celhay O; Irani J; Cussenot O; Fromont G
    Histopathology; 2009 Oct; 55(4):392-8. PubMed ID: 19817889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
    Nordby Y; Andersen S; Richardsen E; Ness N; Al-Saad S; Melbø-Jørgensen C; Patel HR; Dønnem T; Busund LT; Bremnes RM
    Prostate; 2015 Nov; 75(15):1682-93. PubMed ID: 26268996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
    Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
    Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.